1. Home
  2. BIT vs GYRE Comparison

BIT vs GYRE Comparison

Compare BIT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Multi-Sector Income Trust of Beneficial Interest

BIT

BlackRock Multi-Sector Income Trust of Beneficial Interest

N/A

Current Price

$11.92

Market Cap

713.3M

Sector

Finance

ML Signal

N/A

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

N/A

Current Price

$6.93

Market Cap

606.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BIT
GYRE
Founded
N/A
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
713.3M
606.4M
IPO Year
2012
2004

Fundamental Metrics

Financial Performance
Metric
BIT
GYRE
Price
$11.92
$6.93
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$17.00
AVG Volume (30 Days)
361.3K
45.3K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$275,000.00
Revenue This Year
N/A
$19.88
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.88
$5.44
52 Week High
$13.99
$9.42

Technical Indicators

Market Signals
Indicator
BIT
GYRE
Relative Strength Index (RSI) 26.30 60.04
Support Level N/A $6.76
Resistance Level $13.33 $8.28
Average True Range (ATR) 0.09 0.33
MACD -0.03 0.07
Stochastic Oscillator 18.98 69.33

Price Performance

Historical Comparison
BIT
GYRE

About BIT BlackRock Multi-Sector Income Trust of Beneficial Interest

BlackRock Multi-Sector Income Trust is a closed-end investment management company. It invests on behalf of its clients. The fund's primary investment objective is to provide a high level of current income, with a secondary objective of capital appreciation. The company seeks to achieve its investment objectives by investing, under normal market conditions, a majority of its assets in loans and debt instruments and other investments with similar economic characteristics. Its portfolio consists of Corporate Bonds, Asset-Backed Securities, Preferred Securities, and others.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: